High Throughput Genomics Signs Collaboration Agreement with University of California, San Diego
News Sep 11, 2007
Under the terms of the agreement, HTG and UCSD will collaborate to generate arrays using tissue samples from mice as well as various cell lysates to evaluate genes responsible for inflammation and insulin production using HTG’s qNPA™ quantitative Nuclease Protection Assay technology. Dr. Jerry Olefsky is the lead collaborator on the project for UCSD.
One of the key goals for this research program is to study mechanisms of insulin resistance and how inflammation is involved in the pathogenesis of diabetes. Having genes on the array that are markers for inflammation is an effective way for UCSD to assess biomarkers and study the genes in question.
“We are excited about the utility of HTG’s technology platform for a number of reasons including cost effectiveness and time savings by having multiple genes analyzed simultaneously,” said Dr. Jerry Olefsky. “The reliability and reproducibility of the technology will enable our research team to move through our project with great ease and confidence.”
HTG’s qNPA technology is used to carry out quantitative multiplexed, gene-based drug discovery programs, including target validation, HTS lead optimization, metabolism, toxicology and clinical development.
As genome editing technologies advance toward clinical therapies, they are raising hopes of a completely new way to treat disease. However, challenges need to be addressed before potential treatments can be widely used in patients. To tackle these challenges, the National Institutes of Health has launched the Somatic Cell Genome Editing program, which has awarded multiple grants including more than $3.6 million to assess the safety of genome editing in human cells and tissues.